Analyzing R01 Anxiety: There Is Room For Optimism

United States biomedical research is the envy of all other nations. Its success and explosive growth are due to an efficient partnership between public funding and academic research. But this doesn't mean that the partnership is in every respect beyond improvement. Take, for instance, individual investigator-initiated grants (or R01s, in NIH vernacular). The R01 is the instrument by which new ideas can best be tried and developed. Appropriately, these grants have commanded an increasing share

Written byDouglas Kelly
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The R01 is the instrument by which new ideas can best be tried and developed. Appropriately, these grants have commanded an increasing share of the NIH budget; in the past five years alone the number of active R01s has increased by 25 percent.

R01s have evolved to become not only the cornerstone of biomedical research support, but also the prime factor in determining advancement of academic biomedical researchers. In awarding R01s, NIH study sections may now play a more important role in influencing who is appointed, promoted, or granted tenure than do promotion committees.

R01s have also come to provide an increasing proportion of the funds for pre- and postdoctoral training, which carries advantages as well as problems. While it can be argued that training funded by an R01 educates at the leading edge of science, this arrangement places in doubt whether that training is in the broadest educational interest ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies